

091-201088

For Internal Use Only	Submit 1 Original	OMB Approval No.:
Sec File No. 91 -	and 9 Copies	Expires:

RECEIVED

Estimated average burden hours per response: 2.00

UNITED STATES
 SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549
 FORM 19b-4(e)

Information Required of a Self-Regulatory Organization Listing and Trading a New
 Derivative Securities Product Pursuant to Rule 19b-4(e) Under the Securities Exchange Act of 1934

READ ALL INSTRUCTIONS PRIOR TO COMPLETING FORM

Part I Initial Listing Report

1. Name of Self-Regulatory Organization Listing New Derivative Securities Product:

NYSE Arca, Inc. (trading pursuant to unlisted trading privileges)

SEC
 Mail Processing
 Section

2. Type of Issuer of New Derivative Securities Product (e.g., clearinghouse, broker-dealer, corporation, etc.):

Open-end Management Investment Company

FEB 11 2016

3. Class of New Derivative Securities Product:

Investment Company Units

Washington DC
 404

4. Name of Underlying Instrument:

Market Vectors US Listed Biotech 25 Index



5. If Underlying Instrument is an Index, State Whether it is Broad-Based or Narrow-Based:

Narrow-Based

16000137

6. Ticker Symbol(s) of New Derivative Securities Product:

BBH

7. Market or Markets Upon Which Securities Comprising Underlying Instrument Trades:

NYSE, NASDAQ

8. Settlement Methodology of New Derivative Securities Product:

Regular way trades settle on T+3/Book entry only held in DTC.

9. Position Limits of New Derivative Securities Product (if applicable):

Not applicable.

Part II Execution

The undersigned represents that the governing body of the above-referenced Self-Regulatory Organization has duly approved, or has duly delegated its approval to the undersigned for, the listing and trading of the above-referenced new derivative securities product according to its relevant trading rules, procedures, surveillance programs and listing standards.

Name of Official Responsible for Form:

Martha Redding

Title:

Senior Counsel and Assistant Secretary

Telephone Number:

(212) 656-2938

Manual Signature of Official Responsible for Form:

February 8, 2016
 SEC 2449 (1/99)

Act	Securities Exchange Act of 1934
Section	19b-4(e)
Public Availability:	FEB 11 2016



Martha Redding
Senior Counsel
Assistant Secretary

New York Stock Exchange
11 Wall Street
New York, NY 10005
T + 1 212 656 2938
F + 1 212 656 8101
Martha.Redding@theice.com

RECEIVED
FEB 10 10 3 16
SEC / TM

Via Overnight Mail

February 8, 2016

Ms. Gail Jackson
US Securities and Exchange Commission
Division of Trading and Markets
Station Place – Building I
100 F Street, N.E. – Room 6628
Washington, DC 20549

SEC
Mail Processing
Section
FEB 11 2016
Washington DC
404

Re: 19b-4(e) – Transmittal

Dear Ms. Jackson:

Enclosed for filing pursuant to Section 19(b) of the Securities Exchange Act of 1934 and Rule 19b-4 thereunder, please find an original and nine copies of Form 19b-4(e) with respect to the securities listed below.

- Market Vectors Biotech ETF (BBH)**
- Market Vectors Pharmaceutical ETF (PPH)**
- iShares 20+ Year Treasury Bond ETF (TLT)**
- iShares MSCI China ETF (MCHI)**
- iShares MSCI EAFE Small-Cap ETF (SCZ)**
- iShares Core MSCI Total International Stock ETF (IXUS)**
- iShares Global Infrastructure ETF (IGF)**
- iShares Asia 50 ETF (AIA)**
- iShares MSCI Brazil Small-Cap ETF (EWZS)**
- iShares MSCI New Zealand Capped ETF (ENZL)**
- iShares 0-5 Year Investment Grade Corporate Bond ETF (SLQD)**
- iShares Morningstar Mid-Cap Value ETF (JKI)**
- iShares MSCI Eurozone ETF (EZU)**

If you have any questions, please do not hesitate to call me at (212) 656-2938.

Sincerely,


Enclosures

Act	Securities Exchange Act of 1934
Section	19b-4
Rule	19b-4(e)
Public Availability:	FEB 11 2016